Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

Next Previous
X
Search
Trial Profile

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALTO 203 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors Alto Neuroscience

    • Most Recent Events

    • 11 Dec 2024 According to an Alto Neuroscience Inc media release, Company announced presentation of this trial at the 63rd annual meeting of the American College of Neuropsychopharmacology (ACNP), in Phoenix, Arizona, held December 8-11, 2024.
    • 22 Oct 2024 According to an Alto Neuroscience media release, data readout is expected in the first half of 2025.
    • 03 Apr 2024 According to an Alto Neuroscience media release, Alto expects to enroll approximately 60 adult participants with MDD.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top